Page 52 - ARNM-3-1

Advances in Radiotherapy
& Nuclear Medicine EZH2 inhibition in ARID1A-deficient TNBC

82. Lin Z, Huang L, Li SL, Gu J, Cui X, Zhou Y. PTEN loss 93. Vejmelkova K, Pokorna P, Noskova K, et al. Tazemetostat in
correlates with T cell exclusion across human cancers. BMC the therapy of pediatric INI1-negative malignant rhabdoid
Cancer. 2021;21(1):429. tumors. Sci Rep. 2023;13(1):21623.
doi: 10.1186/s12885-021-08114-x doi: 10.1038/s41598-023-48774-2
83. Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon 94. Chen X, Wu J, Pang G, Wei S, Wang P. Integrase interactor
receptor signaling pathways regulating PD-L1 and Pd-L2 1 (INI1) deficiency in a lung cancer patient presents
expression. Cell Rep. 2017;19(6):1189-1201. nonresponse to immunotherapy and tazemetostat: A Case
doi: 10.1016/j.celrep.2017.04.031 report. Cureus. 2023;15(8):e42934.
84. Wang X, Yang L, Huang F, et al. Inflammatory cytokines doi: 10.7759/cureus.42934
IL-17 and TNF-Α up-regulate PD-L1 expression in human 95. Narvaez D, Nadal J, Nervo A, et al. The emerging role of
prostate and colon cancer cells. Immunol Lett. 2017;184:7-14. tertiary lymphoid structures in breast cancer: A narrative
doi: 10.1016/j.imlet.2017.02.006 review. Cancers (Basel). 2024;16(2):396.
85. Zhao Y, Wang XX, Wu W, et al. EZH2 Regulates PD-L1 doi: 10.3390/cancers16020396
expression via HIF-1α in non-small cell lung cancer cells. 96. Grapin M, Richard C, Limagne E, et al. Optimized
Biochem Biophys Res Commun. 2019;517(2):201-209. fractionated radiotherapy with anti-PD-L1 and anti-tigit:
doi: 10.1016/j.bbrc.2019.07.039 A promising new combination. J Immunother Cancer.
2019;7(1):160.
86. Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting
EZH2 enhances antigen presentation, antitumor immunity, doi: 10.1186/s40425-019-0634-9
and circumvents anti-PD-1 resistance in head and neck 97. Smits KM, Melotte V, Niessen HE, et al. Epigenetics in
cancer. Clin Cancer Res. 2020;26(1):290-300. radiotherapy: Where are we heading? Radiother Oncol.
doi: 10.1158/1078-0432.Ccr-19-1351 2014;111(2):168-177.

87. Xiao G, Jin LL, Liu CQ, et al. EZH2 negatively regulates PD-L1 doi: 10.1016/j.radonc.2014.05.001
expression in hepatocellular carcinoma. J Immunother 98. Johnson AB, Denko N, Barton MC. Hypoxia induces a novel
Cancer. 2019;7(1):300. signature of chromatin modifications and global repression
doi: 10.1186/s40425-019-0784-9 of transcription. Mutat Res. 2008;640(1-2):174-179.
88. Qiu F, Yang Q, Sun W, Ruan K, Jiang N, Zhou J. EZH2 doi: 10.1016/j.mrfmmm.2008.01.001
inhibition activates dsrna-interferon axis stress and 99. Trappetti V, Fazzari JM, Fernandez-Palomo C, et al.
promotes response to PD-1 checkpoint blockade in NSCLC. Microbeam radiotherapy-a novel therapeutic approach
J Cancer. 2022;13(9):2893-2904. to overcome radioresistance and enhance anti-tumour
doi: 10.7150/jca.73291 response in melanoma. Int J Mol Sci. 2021;22(14):7755.
89. Li C, Wang Y, Gong Y, et al. Finding an easy way to doi: 10.3390/ijms22147755
harmonize: A review of advances in clinical research and 100. Andrade D, Mehta M, Griffith J, et al. HuR reduces radiation-
combination strategies of EZH2 inhibitors. Clin Epigenetics. induced DNA damage by enhancing expression of arid1a.
2021;13(1):62. Cancers (Basel). 2019;11(12):2014.
doi: 10.1186/s13148-021-01045-1 doi: 10.3390/cancers11122014
90. Goswami S, Apostolou I, Zhang J, et al. Modulation of EZH2 101. Bakr A, Della Corte G, Veselinov O, et al. ARID1A
expression in T cells improves efficacy of anti-CTLA-4 regulates DNA repair through chromatin organization and
therapy. J Clin Invest. 2018;128(9):3813-3818. its deficiency triggers DNA damage-mediated anti-tumor
doi: 10.1172/jci99760 immune response. Nucleic Acids Res. 2024;52(10):5698-5719.
91. Guo R, Li J, Hu J, et al. Combination of epidrugs with immune doi: 10.1093/nar/gkae233
checkpoint inhibitors in cancer immunotherapy: From 102. Sak A, Kübler D, Bannik K, et al. Epigenetic silencing
theory to therapy. Int Immunopharmacol. 2023;120:110417. and activation of transcription: Influence on the
doi: 10.1016/j.intimp.2023.110417 radiation sensitivity of glioma cell lines. Int J Radiat Biol.
2017;93(5):494-506.
92. Zingg D, Arenas-Ramirez N, Sahin D, et al. The
histone methyltransferase EZH2 controls mechanisms doi: 10.1080/09553002.2017.1270472
of adaptive resistance to tumor immunotherapy. Cell 103. Alimova I, Birks DK, Harris PS, et al. Inhibition of EZH2
Rep. 2017;20(4):854-867.
suppresses self-renewal and induces radiation sensitivity
doi: 10.1016/j.celrep.2017.07.007 in atypical rhabdoid teratoid tumor cells. Neuro Oncol.

Volume 3 Issue 1 (2025) 44 doi: 10.36922/arnm.5132